top of page

Do you have non-alcoholic fatty liver disease (NAFLD)?

NAFLD is a condition where there is an accumulation of fatty cells in the liver. NAFLD is becoming more common and is found in about 25% of the general population worldwide. People with NAFLD have a higher than average risk of chronic liver disease, cirrhosis, and one kind of liver cancer, hepatocellular carcinoma (HCC). HCC is increasing more rapidly than any other cancer in the United States, due mainly to an increase in NAFLD in the general population.
The usual approach for patients diagnosed with NAFLD is to be followed closely by their doctor to watch for worsening of liver disease, which could include the development of cirrhosis and cancer. Imaging studies – tests that take pictures of your liver – and blood tests are done every 6-12 months. Weight loss, healthy diet and exercise are the recommended treatments for non-alcoholic fatty liver diseases. Currently, there is no Food and Drug Administration (FDA) approval for any drugs to treat NAFLD.

I have colon polyps: Welcome
NWU2015-06-01

Role of lisinopril in preventing the progression of non-alcoholic fatty liver disease

Principal Investigator: Ju Dong Yang, MD
Cedars-Sinai Medical Center

Cedars-Sinai Medical Center

This study will test the effects of lisinopril on people’s risk of developing hepatocellular carcinoma (HCC). Lisinopril is a medication that has been commonly used to treat high blood pressure since 1987 in the U.S. Participants in this study will receive 10 mg of lisinopril orally once daily for up to 24 weeks, in addition to their standard of care. This will allow researchers to see if participants taking lisinopril show changes in their liver, which may indicate a lower risk of developing cancer. This study is looking for volunteers who are 18 years of age or older and have NAFLD. We will enroll 40 participants.


You may be eligible if:
• You have a higher than average risk of developing liver cancer due to your diagnosis of NAFLD
• You have advanced fibrosis (scarring)

 

If you think you may be eligible, you can contact a study coordinator at your preferred location from the list below:

CEDARS-SINAI MEDICAL CENTER – Manaf Alsudaney (310) 967-7454 manaf.alsudaney@cshs.org – Los Angeles, California
DUKE UNIVERSITY –
Magdi Elgasim (919) 684-9019
magdi.elgasim@duke.edu – Durham, North Carolina
MOUNT SINAI HEALTH SYSTEM –
Clara Rodriguez Rivas (212) 824-7587 clara.rodriguezrivas@mountsinai.org – New York, New York
MAYO CLINIC –
Emmanuel Ogbu (763) 501-4388
ogbu.emmanuel@mayo.edu – Rochester, Minnesota

 

More Information:  https://clinicaltrials.gov/ct2/show/NCT04550481

Additional Resources

Study Brochure 

NWU20-01-03 Lisinopril Slide 1.PNG
NWU20-01-03 Lisinopril Slide 2.PNG
bottom of page